Hydroxycamptothecin

Hydroxycamptothecin

SCHEMBL25875

CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3cc(O)ccc3nc2-1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TOP1 P11387 18/20 1.00
MEN1 O00255 4/20 1.00
KMT2A Q03164 4/20 1.00
SMN1; SMN2 Q16637 4/20 1.00
ALDH1A1 P00352 4/20 1.00
KDM4E B2RXH2 3/20 1.00
CYP3A4 P08684 2/20 1.00
HBB P68871 2/20 1.00
CASP1 P29466 1/20 1.00
CASP7 P55210 1/20 1.00
GLA P06280 3/20 0.80
TP53 P04637 2/20 0.80
HPGD P15428 2/20 0.80
STAT6 P42226 1/20 0.80
CHEK1 O14757 1/20 0.80
HDAC3 O15379 1/20 0.80
ABCC4 O15439 1/20 0.80
GMNN O75496 1/20 0.80
LMNA P02545 1/20 0.80
CYP1A2 P05177 1/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydroxycamptothecin SCHEMBL29350707 1.00 TOP1 (1.00) TOP1MEN1KMT2ASMN1; SMN2ALDH1A1
Hydroxycamptothecin SCHEMBL9384413 1.00 TOP1 (1.00) TOP1MEN1KMT2ASMN1; SMN2ALDH1A1
Hydroxycamptothecin SCHEMBL29929278 1.00 TOP1 (1.00) TOP1MEN1KMT2ASMN1; SMN2ALDH1A1
Hydroxycamptothecin SCHEMBL27713853 0.99 TOP1 (0.98) TOP1MEN1KMT2ASMN1; SMN2ALDH1A1
Hydroxycamptothecin SCHEMBL27638187 0.99 TOP1 (0.98) TOP1MEN1KMT2ASMN1; SMN2ALDH1A1
Hydroxycamptothecin SCHEMBL26683387 0.99 TOP1 (0.98) TOP1MEN1KMT2ASMN1; SMN2ALDH1A1
Hydroxycamptothecin SCHEMBL30872708 0.99 TOP1 (0.98) TOP1MEN1KMT2ASMN1; SMN2ALDH1A1
Hydroxycamptothecin SCHEMBL28836816 0.99 TOP1 (0.98) TOP1MEN1KMT2ASMN1; SMN2ALDH1A1
Hydroxycamptothecin SCHEMBL30426602 0.99 TOP1 (0.98) TOP1MEN1KMT2ASMN1; SMN2ALDH1A1
Hydroxycamptothecin SCHEMBL27466705 0.99 TOP1 (0.98) TOP1MEN1KMT2ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 13939 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260144882-A1 ANTI-NECTIN-4 ANTIBODY DRUG CONJUGATE AND USE THEREOF BIO-THERA SOLUTIONS, LTD. (CN) 2026-05-28 US claimed
US-20260137796-A1 PHARMACEUTICAL COMBINATIONS FOR SUBCUTANEOUS ADMINISTRATION AND USE THEREOF SHANGHAI BAO PHARMACEUTICALS CO., LTD. (CN) 2026-05-21 US claimed
EP-4744680-A1 TARGETED CHEMICAL DRUG AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USE OF TARGETED CHEMICAL DRUG Bai Yao Zhi Da (Beijing) Nanobio Technology Co., Ltd. (CN) 2026-05-20 EP claimed
EP-3841097-B1 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) 2026-05-20 EP claimed
CN-122060700-A Enzymatic reaction catalyst and application thereof in synthesis of 10-hydroxycamptothecin-glucoside 苏州泳菖生物科技有限公司 2026-05-19 CN claimed
WO-2026098621-A1 ENGINEERED ANTIBODY WITH SITE-SPECIFIC CONJUGATION, ANTIBODY-DRUG CONJUGATE, AND APPLICATION THEREOF 百力司康生物医药(杭州)有限公司 2026-05-15 WO claimed
EP-4740956-A1 PHARMACEUTICAL COMBINATION FOR SUBCUTANEOUS ADMINISTRATION AND USE THEREOF Shanghai Bao Pharmaceuticals Co., Ltd. (CN) 2026-05-13 EP claimed
CN-122028934-A Combination of CLDN18_2 antibody and chemotherapeutic drug and application thereof 江苏奥赛康生物医药有限公司 2026-05-12 CN claimed
CN-122011189-A Anti-CEACAM 5 antibody or antigen binding fragment thereof and application thereof 上海生物制品研究所有限责任公司 2026-05-12 CN claimed
CN-122011405-A For Cu2+Zinc (II) metal organic framework material for NB detection and photocatalytic degradation of organic dye and preparation method thereof 陕西理工大学 2026-05-12 CN claimed
WO-1994005672-A1 PROCESS FOR PREPARING CERTAIN PYRROLO[3,4- b]QUINOLINES, CERTAIN 1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-b]QUINOLIN-3,14(4H,12H)-DIONES, AND CERTAIN 8-METHYL-7-(OXOPROPYL)-INDOLIZINO[1,2-b]QUINOLIN-9(11H)-ONES SMITHKLINE BEECHAM CORPORATION (US) 1994-03-17 WO claimed
EP-0547165-A1 WATER SOLUBLE CAMPTOTHECIN ANALOGUES, PROCESSES AND METHODS SMITHKLINE BEECHAM CORPORATION (US) 1993-06-23 EP claimed
CN-1062731-A Water soluble camptothecin analogs and intermediates preparation thereof are by the compound and the using method thereof of described method preparation SMITHKLINE BEECHAM CORP (US) 1992-07-15 CN claimed
WO-1992005785-A1 WATER SOLUBLE CAMPTOTHECIN ANALOGUES, PROCESSES AND METHODS SMITHKLINE BEECHAM CORPORATION (US) 1992-04-16 WO claimed
CN-1012376-B Method for producing 10-hydroxycamptothecin by biotransformation SHANGHAI INST OF MEDICINE CHIN (CN) 1991-04-17 CN claimed
CN-1034724-A WATER SOLUBLE CAMPTOTHECIN ANALOGS SMITHKLINE BECKMAN CORP (US) 1989-08-16 CN claimed
EP-0321122-A2 Water soluble camptothecin analogs SMITHKLINE BEECHAM CORPORATION (US) 1989-06-21 EP claimed
EP-0137145-B1 NEW CAMPTOTHECIN DERIVATIVES AND PROCESS FOR PREPARING SAME KABUSHIKI KAISHA YAKULT HONSHA (JP) 1988-04-27 EP claimed
CN-85100520-A Produce the method for 10-hydroxycamptothecine with bio-transformation 1986-08-13 CN claimed
EP-0137145-A1 New camptothecin derivatives and process for preparing same KABUSHIKI KAISHA YAKULT HONSHA (JP) 1985-04-17 EP claimed